Candriam S.C.A. Arcutis Biotherapeutics, Inc. Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARQT
# of Institutions
197Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC11.7MShares$158 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$149 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$145 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$119 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$117 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $817M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...